
Prelude Therapeutics Incorporated PRLD
€ 3.43
0.53%
Prelude Therapeutics Incorporated Gesamtes Eigenkapital | PRLD
Gesamtes Eigenkapital Jährlich Prelude Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.6 M | 131 M | 237 M | 195 M | 286 M | 212 M | -49.4 M | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 286 M | -49.4 M | 154 M |
Gesamtes Eigenkapital Vierteljährlich Prelude Therapeutics Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 M | 60.2 M | 237 M | 58.5 M | 75.8 M | 103 M | 195 M | 156 M | 182 M | 211 M | 286 M | 238 M | 262 M | 175 M | - | 217 M | 241 M | 262 M | 286 M | 311 M | 334 M | 357 M | 212 M | 212 M | 212 M | 212 M | -49.4 M | -49.4 M | -33.3 M | -27.9 M | -22.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 357 M | -49.4 M | 168 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
212 M | $ 4.2 | -0.36 % | $ 651 M | ||
|
AbbVie
ABBV
|
-3.27 B | $ 294.72 | 0.32 % | $ 521 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
15.8 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | ||
|
Achieve Life Sciences
ACHV
|
21.5 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Axon Enterprise
AXON
|
3.24 B | $ 316.97 | 4.77 % | $ 24.7 B | ||
|
TFF Pharmaceuticals
TFFP
|
9.57 M | - | -60.05 % | $ 125 K | ||
|
Bristol-Myers Squibb Company
BMY
|
18.5 B | $ 62.89 | 0.18 % | $ 128 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
11.8 M | - | -15.15 % | $ 60.3 M | ||
|
Axcella Health
AXLA
|
4.16 M | - | -16.42 % | $ 249 M | ||
|
Cytokinetics, Incorporated
CYTK
|
-660 M | $ 58.59 | 4.29 % | $ 7.04 M | ||
|
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 159.75 | 5.35 % | $ 20.9 B | ||
|
Amgen
AMGN
|
8.66 B | $ 467.97 | 0.59 % | $ 252 B | ||
|
Orgenesis
ORGS
|
-37.5 M | - | -33.86 % | $ 61.2 M | ||
|
Codiak BioSciences
CDAK
|
53.5 M | - | -55.98 % | $ 2.15 M | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
4.32 B | $ 248.31 | 1.17 % | $ 15.1 B | ||
|
Johnson & Johnson
JNJ
|
81.5 B | $ 280.31 | -0.17 % | $ 675 B | ||
|
Kala Pharmaceuticals
KALA
|
7 M | $ 0.17 | 0.64 % | $ 1.39 M | ||
|
BioLineRx Ltd.
BLRX
|
23.3 M | $ 1.49 | -1.97 % | $ 3.67 B | ||
|
Sage Therapeutics
SAGE
|
465 M | - | - | $ 527 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 1.59 | -2.76 % | $ 2.62 M | ||
|
Lineage Cell Therapeutics
LCTX
|
44.5 M | $ 1.13 | 8.17 % | $ 260 M | ||
|
Paratek Pharmaceuticals
PRTK
|
-171 M | - | - | $ 121 M | ||
|
TCR2 Therapeutics
TCRR
|
141 M | - | - | $ 58.1 M | ||
|
C4 Therapeutics
CCCC
|
257 M | $ 2.9 | -3.5 % | $ 240 M | ||
|
Eli Lilly and Company
LLY
|
26.5 B | $ 1 437.4 | 0.36 % | $ 1.29 T | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
-13.3 M | - | -14.27 % | $ 1.7 M | ||
|
Compugen Ltd.
CGEN
|
103 M | $ 2.09 | -0.24 % | $ 195 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
992 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
GeoVax Labs
GOVX
|
3.83 M | $ 2.13 | -20.4 % | $ 2.04 M | ||
|
Unity Biotechnology
UBX
|
6.49 M | - | -33.41 % | $ 3.37 M | ||
|
MediciNova
MNOV
|
41.6 M | $ 1.41 | 0.36 % | $ 69.2 M | ||
|
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | ||
|
Seelos Therapeutics
SEEL
|
-33.5 M | - | -47.76 % | $ 6.27 M | ||
|
Celldex Therapeutics
CLDX
|
527 M | $ 30.18 | -1.53 % | $ 2 B | ||
|
Moderna
MRNA
|
8.65 B | $ 248.62 | -0.88 % | $ 96.7 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
6.08 M | $ 3.96 | 1.41 % | $ 48.3 M | ||
|
Kiromic BioPharma
KRBP
|
-12.6 M | - | 6.61 % | $ 3.08 M | ||
|
Nektar Therapeutics
NKTR
|
89.8 M | $ 38.41 | 1.67 % | $ 648 M | ||
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | ||
|
CorMedix
CRMD
|
405 M | $ 5.31 | -2.23 % | $ 383 K | ||
|
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 45.39 | 0.53 % | $ 4.08 B | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
5.44 M | $ 1.66 | -2.64 % | $ 1.12 B | ||
|
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | ||
|
Idera Pharmaceuticals
IDRA
|
11.8 M | - | -23.04 % | $ 26.6 M | ||
|
Tyme Technologies
TYME
|
80.1 M | - | 8.07 % | $ 54 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
205 M | - | - | $ 69.7 B |